April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
9 citations
,
January 2024 in “International Journal of Dermatology”
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
November 2024 in “Rheumatology Advances in Practice” Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
2 citations
,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
20 citations
,
March 2017 in “Arthritis research & therapy” Social media can help compare the effectiveness and safety of new arthritis medications.
80 citations
,
August 1991 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Methotrexate reduced the need for steroids in asthma patients without worsening their condition.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.